Annual Short Term Debt
$5.40 B
-$142.00 M-2.56%
31 December 2023
Summary:
AstraZeneca annual short term debt is currently $5.40 billion, with the most recent change of -$142.00 million (-2.56%) on 31 December 2023. During the last 3 years, it has risen by +$3.01 billion (+126.32%). AZN annual short term debt is now -2.56% below its all-time high of $5.54 billion, reached on 31 December 2022.AZN Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Short Term Debt
$1.57 B
-$3.79 B-70.70%
30 September 2024
Summary:
AstraZeneca quarterly short term debt is currently $1.57 billion, with the most recent change of -$3.79 billion (-70.70%) on 30 September 2024. Over the past year, it has dropped by -$4.04 billion (-72.00%). AZN quarterly short term debt is now -89.05% below its all-time high of $14.34 billion, reached on 30 June 2007.AZN Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Short Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.6% | -72.0% |
| 3 y3 years | +126.3% | -47.2% |
| 5 y5 years | +207.9% | +172.1% |
AZN Short Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -2.6% | +185.3% | -75.2% | at low |
| 5 y | 5 years | -2.6% | +207.9% | -75.2% | +172.1% |
| alltime | all time | -2.6% | +5900.0% | -89.0% | +2746.6% |
AstraZeneca Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.57 B(-70.7%) |
| June 2024 | - | $5.36 B(-15.4%) |
| Mar 2024 | - | $6.33 B(+17.2%) |
| Dec 2023 | $5.40 B(-2.6%) | $5.40 B(-3.7%) |
| Sept 2023 | - | $5.61 B(+17.1%) |
| June 2023 | - | $4.79 B(+24.1%) |
| Mar 2023 | - | $3.86 B(-30.4%) |
| Dec 2022 | $5.54 B(+192.8%) | $5.54 B(-1.4%) |
| Sept 2022 | - | $5.62 B(+135.9%) |
| June 2022 | - | $2.38 B(+3.8%) |
| Mar 2022 | - | $2.29 B(+21.2%) |
| Dec 2021 | $1.89 B(-20.7%) | $1.89 B(-36.3%) |
| Sept 2021 | - | $2.97 B(+2.7%) |
| June 2021 | - | $2.89 B(+28.2%) |
| Mar 2021 | - | $2.26 B(-5.4%) |
| Dec 2020 | $2.39 B(+18.7%) | $2.39 B(-33.4%) |
| Sept 2020 | - | $3.58 B(-13.2%) |
| June 2020 | - | $4.13 B(+67.3%) |
| Mar 2020 | - | $2.47 B(+22.9%) |
| Dec 2019 | $2.01 B(+14.6%) | $2.01 B(+248.4%) |
| Sept 2019 | - | $577.00 M(-68.6%) |
| June 2019 | - | $1.83 B(-50.7%) |
| Mar 2019 | - | $3.72 B(+112.0%) |
| Dec 2018 | $1.75 B(-21.9%) | $1.75 B(-29.6%) |
| Sept 2018 | - | $2.49 B(-40.9%) |
| June 2018 | - | $4.21 B(+1.1%) |
| Mar 2018 | - | $4.17 B(+85.6%) |
| Dec 2017 | $2.25 B(-2.6%) | $2.25 B(+138.8%) |
| Sept 2017 | - | $941.00 M(-67.9%) |
| June 2017 | - | $2.93 B(+3.3%) |
| Mar 2017 | - | $2.84 B(+23.1%) |
| Dec 2016 | $2.31 B(+151.9%) | $2.31 B(-21.5%) |
| Sept 2016 | - | $2.94 B(+177.3%) |
| June 2016 | - | $1.06 B(-51.1%) |
| Mar 2016 | - | $2.17 B(+136.7%) |
| Dec 2015 | $916.00 M(-62.6%) | $916.00 M(-65.7%) |
| Sept 2015 | - | $2.67 B(-1.3%) |
| June 2015 | - | $2.71 B(+17.7%) |
| Mar 2015 | - | $2.30 B(-6.0%) |
| Dec 2014 | $2.45 B(+36.8%) | $2.45 B(+2.0%) |
| Sept 2014 | - | $2.40 B(-4.0%) |
| June 2014 | - | $2.50 B(-10.3%) |
| Mar 2014 | - | $2.79 B(+55.9%) |
| Dec 2013 | $1.79 B(+98.4%) | $1.79 B(+4.6%) |
| Sept 2013 | - | $1.71 B(-9.1%) |
| June 2013 | - | $1.88 B(+111.5%) |
| Mar 2013 | - | $889.00 M(-1.3%) |
| Dec 2012 | $901.00 M(-54.7%) | $901.00 M(-42.5%) |
| Sept 2012 | - | $1.57 B(-22.0%) |
| June 2012 | - | $2.01 B(+0.1%) |
| Mar 2012 | - | $2.01 B(+0.8%) |
| Dec 2011 | $1.99 B | $1.99 B(-3.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $2.06 B(+452.4%) |
| June 2011 | - | $372.00 M(-14.5%) |
| Mar 2011 | - | $435.00 M(+248.0%) |
| Dec 2010 | $125.00 M(-93.5%) | $125.00 M(-90.9%) |
| Sept 2010 | - | $1.38 B(+7.9%) |
| June 2010 | - | $1.27 B(-0.2%) |
| Mar 2010 | - | $1.28 B(-33.7%) |
| Dec 2009 | $1.93 B(+94.0%) | $1.93 B(+96.5%) |
| Sept 2009 | - | $980.00 M(-34.6%) |
| June 2009 | - | $1.50 B(-8.0%) |
| Mar 2009 | - | $1.63 B(+63.9%) |
| Dec 2008 | $993.00 M(-76.8%) | $993.00 M(-61.0%) |
| Sept 2008 | - | $2.55 B(-33.7%) |
| June 2008 | - | $3.84 B(-1.2%) |
| Mar 2008 | - | $3.89 B(-9.2%) |
| Dec 2007 | $4.28 B(+3047.1%) | $4.28 B(-20.8%) |
| Sept 2007 | - | $5.40 B(-62.3%) |
| June 2007 | - | $14.34 B(>+9900.0%) |
| Mar 2007 | - | $59.00 M(-56.6%) |
| Dec 2006 | $136.00 M(+51.1%) | $136.00 M(+20.4%) |
| Sept 2006 | - | $113.00 M(+32.9%) |
| June 2006 | - | $85.00 M(-37.5%) |
| Mar 2006 | - | $136.00 M(+51.1%) |
| Dec 2005 | $90.00 M(-36.6%) | $90.00 M(-26.2%) |
| Sept 2005 | - | $122.00 M(-18.7%) |
| June 2005 | - | $150.00 M(+66.7%) |
| Mar 2005 | - | $90.00 M(-36.6%) |
| Dec 2004 | $142.00 M(-6.6%) | $142.00 M(-16.5%) |
| Sept 2004 | - | $170.00 M(+66.7%) |
| June 2004 | - | $102.00 M(+41.7%) |
| Mar 2004 | - | $72.00 M(-52.6%) |
| Dec 2003 | $152.00 M(-70.5%) | $152.00 M(+175.6%) |
| June 2003 | - | $55.15 M(-89.3%) |
| Dec 2002 | $516.00 M(+60.7%) | $516.00 M(+7.8%) |
| June 2002 | - | $478.71 M(+49.1%) |
| Dec 2001 | $321.00 M(+50.3%) | $321.00 M(+21.2%) |
| June 2001 | - | $264.94 M(+24.0%) |
| Dec 2000 | $213.59 M(-43.6%) | $213.59 M(-51.9%) |
| June 2000 | - | $444.06 M(+17.2%) |
| Dec 1999 | $379.00 M(+0.5%) | $379.00 M(-0.8%) |
| Sept 1999 | - | $382.00 M(-43.7%) |
| June 1999 | - | $678.00 M(+79.8%) |
| Dec 1998 | $377.00 M(+22.0%) | $377.00 M(-24.0%) |
| June 1998 | - | $496.00 M(+60.4%) |
| Dec 1997 | $309.13 M(-22.2%) | $309.13 M(-22.2%) |
| Dec 1996 | $397.30 M(-5.1%) | $397.30 M(-5.1%) |
| Dec 1995 | $418.75 M(+20.7%) | $418.75 M(-12.5%) |
| June 1995 | - | $478.40 M(+37.8%) |
| Dec 1994 | $347.08 M(-65.7%) | $347.08 M(-65.7%) |
| Dec 1993 | $1.01 B(-51.7%) | $1.01 B |
| Dec 1992 | $2.10 B(+946.9%) | - |
| Dec 1991 | $200.22 M(+12.8%) | - |
| Dec 1990 | $177.46 M | - |
FAQ
- What is AstraZeneca annual short term debt?
- What is the all time high annual short term debt for AstraZeneca?
- What is AstraZeneca annual short term debt year-on-year change?
- What is AstraZeneca quarterly short term debt?
- What is the all time high quarterly short term debt for AstraZeneca?
- What is AstraZeneca quarterly short term debt year-on-year change?
What is AstraZeneca annual short term debt?
The current annual short term debt of AZN is $5.40 B
What is the all time high annual short term debt for AstraZeneca?
AstraZeneca all-time high annual short term debt is $5.54 B
What is AstraZeneca annual short term debt year-on-year change?
Over the past year, AZN annual short term debt has changed by -$142.00 M (-2.56%)
What is AstraZeneca quarterly short term debt?
The current quarterly short term debt of AZN is $1.57 B
What is the all time high quarterly short term debt for AstraZeneca?
AstraZeneca all-time high quarterly short term debt is $14.34 B
What is AstraZeneca quarterly short term debt year-on-year change?
Over the past year, AZN quarterly short term debt has changed by -$4.04 B (-72.00%)